126 related articles for article (PubMed ID: 29359968)
1. In vitro effects of doxorubicin and tetrathiomolybdate on canine hemangiosarcoma cells.
Sloan CQ; Rodriguez CO
Am J Vet Res; 2018 Feb; 79(2):219-225. PubMed ID: 29359968
[TBL] [Abstract][Full Text] [Related]
2. Anticancer effects of resveratrol in canine hemangiosarcoma cell lines.
Carlson A; Alderete KS; Grant MKO; Seelig DM; Sharkey LC; Zordoky BNM
Vet Comp Oncol; 2018 Jun; 16(2):253-261. PubMed ID: 29235249
[TBL] [Abstract][Full Text] [Related]
3. In vitro effects of PI3K/mTOR inhibition in canine hemangiosarcoma.
Pyuen AA; Meuten T; Rose BJ; Thamm DH
PLoS One; 2018; 13(7):e0200634. PubMed ID: 30011343
[TBL] [Abstract][Full Text] [Related]
4. Tetrathiomolybdate sensitizes ovarian cancer cells to anticancer drugs doxorubicin, fenretinide, 5-fluorouracil and mitomycin C.
Kim KK; Lange TS; Singh RK; Brard L; Moore RG
BMC Cancer; 2012 Apr; 12():147. PubMed ID: 22502731
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of anticancer effects and enhanced doxorubicin cytotoxicity of xanthine derivatives using canine hemangiosarcoma cell lines.
Motegi T; Katayama M; Uzuka Y; Okamura Y
Res Vet Sci; 2013 Oct; 95(2):600-5. PubMed ID: 23871419
[TBL] [Abstract][Full Text] [Related]
6. In vitro effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine hemangiosarcoma cell lines.
Lyles SE; Milner RJ; Kow K; Salute ME
Vet Comp Oncol; 2012 Sep; 10(3):223-35. PubMed ID: 22594682
[TBL] [Abstract][Full Text] [Related]
7. Canine hemangiosarcoma treated with standard chemotherapy and minocycline.
Sorenmo K; Duda L; Barber L; Cronin K; Sammarco C; Usborne A; Goldschmidt M; Shofer F
J Vet Intern Med; 2000; 14(4):395-8. PubMed ID: 10935889
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma.
U'Ren LW; Biller BJ; Elmslie RE; Thamm DH; Dow SW
J Vet Intern Med; 2007; 21(1):113-20. PubMed ID: 17338158
[TBL] [Abstract][Full Text] [Related]
9. Canine visceral hemangiosarcoma treated with surgery alone or surgery and doxorubicin: 37 cases (2005-2014).
Batschinski K; Nobre A; Vargas-Mendez E; Tedardi MV; Cirillo J; Cestari G; Ubukata R; Dagli MLZ
Can Vet J; 2018 Sep; 59(9):967-972. PubMed ID: 30197439
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic potential of endothelin inhibitors in canine hemangiosarcoma.
Fukumoto S; Saida K; Sakai H; Ueno H; Iwano H; Uchide T
Life Sci; 2016 Aug; 159():55-60. PubMed ID: 26835989
[TBL] [Abstract][Full Text] [Related]
11. High drug efflux pump capacity and low DNA damage response induce doxorubicin resistance in canine hemangiosarcoma cell lines.
Morita A; Aoshima K; Gulay KCM; Onishi S; Shibata Y; Yasui H; Kobayashi A; Kimura T
Res Vet Sci; 2019 Dec; 127():1-10. PubMed ID: 31648115
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and toxicity of a dose-intensified doxorubicin protocol in canine hemangiosarcoma.
Sorenmo KU; Baez JL; Clifford CA; Mauldin E; Overley B; Skorupski K; Bachman R; Samluk M; Shofer F
J Vet Intern Med; 2004; 18(2):209-13. PubMed ID: 15058772
[TBL] [Abstract][Full Text] [Related]
13. Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma.
Gardner HL; London CA; Portela RA; Nguyen S; Rosenberg MP; Klein MK; Clifford C; Thamm DH; Vail DM; Bergman P; Crawford-Jakubiak M; Henry C; Locke J; Garrett LD
BMC Vet Res; 2015 Jun; 11():131. PubMed ID: 26062540
[TBL] [Abstract][Full Text] [Related]
14. Clinical and pharmacokinetic characteristics of intracavitary administration of pegylated liposomal encapsulated doxorubicin in dogs with splenic hemangiosarcoma.
Sorenmo K; Samluk M; Clifford C; Baez J; Barrett JS; Poppenga R; Overley B; Skorupski K; Oberthaler K; Van Winkle T; Seiler G; Shofer F
J Vet Intern Med; 2007; 21(6):1347-54. PubMed ID: 18196746
[TBL] [Abstract][Full Text] [Related]
15. Comparison of doxorubicin-cyclophosphamide with doxorubicin-dacarbazine for the adjuvant treatment of canine hemangiosarcoma.
Finotello R; Stefanello D; Zini E; Marconato L
Vet Comp Oncol; 2017 Mar; 15(1):25-35. PubMed ID: 25623994
[TBL] [Abstract][Full Text] [Related]
16. Tetrathiomolybdate induces doxorubicin sensitivity in resistant tumor cell lines.
Kim KK; Kawar NM; Singh RK; Lange TS; Brard L; Moore RG
Gynecol Oncol; 2011 Jul; 122(1):183-9. PubMed ID: 21529906
[TBL] [Abstract][Full Text] [Related]
17. Antiangiogenic tetrathiomolybdate enhances the efficacy of doxorubicin against breast carcinoma.
Pan Q; Bao LW; Kleer CG; Brewer GJ; Merajver SD
Mol Cancer Ther; 2003 Jul; 2(7):617-22. PubMed ID: 12883034
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin and deracoxib adjuvant therapy for canine splenic hemangiosarcoma: a pilot study.
Kahn SA; Mullin CM; de Lorimier LP; Burgess KE; Risbon RE; Fred RM; Drobatz K; Clifford CA
Can Vet J; 2013 Mar; 54(3):237-42. PubMed ID: 23997259
[TBL] [Abstract][Full Text] [Related]
19. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial.
Vail DM; MacEwen EG; Kurzman ID; Dubielzig RR; Helfand SC; Kisseberth WC; London CA; Obradovich JE; Madewell BR; Rodriguez CO
Clin Cancer Res; 1995 Oct; 1(10):1165-70. PubMed ID: 9815908
[TBL] [Abstract][Full Text] [Related]
20. Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs.
Lana S; U'ren L; Plaza S; Elmslie R; Gustafson D; Morley P; Dow S
J Vet Intern Med; 2007; 21(4):764-9. PubMed ID: 17708397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]